Sign in
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Journal article   Peer reviewed

Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer

Alaa G Almagthali, Eman H Alkhaldi, Afnan S Alzahrani, Ameera K Alghamdi, Waleed Y Alghamdi and Ahmed M Kabel
Diabetes & metabolic syndrome clinical research & reviews, Vol.13(1), pp.36-39
01/2019
PMID: 30641726

Abstract

Dipeptidyl peptidase-4 inhibitors Patients Diabetes mellitus Cancer
Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.

Metrics

4 Record Views

Details